Last reviewed · How we verify
NCT02267967
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Completed
Phase 1
Last updated 13 November 2018
What this trial tests
Phase 1 trial testing Sulfatinib in Neuroendocrine Tumors in 81 participants. Completed in 23 August 2017.
Timeline
31 October 2014
Primary endpoint
23 August 2017
23 August 2017
23 August 2017
Quick facts
| Lead sponsor | Hutchison Medipharma Limited |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 81 |
| Start date | 31 October 2014 |
| Primary completion | 23 August 2017 |
| Estimated completion | 23 August 2017 |
| Sites | 7 locations across China |
Drugs / interventions tested
- Sulfatinib — full drug profile →
Conditions studied
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
Hutchison Medipharma Limited — full company profile →
Who can join
18 and older, any sex, with Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy.
Patel SA, Nilsson MB, Le X, Cascone T, et al · · 2023 · cited 321× · PMID 35969170 · DOI 10.1158/1078-0432.ccr-22-1366 -
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.
Qin S, Li A, Yi M, Yu S, et al · · 2019 · cited 221× · PMID 30866992 · DOI 10.1186/s13045-019-0718-5 -
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.
Xu JM, Wang Y, Chen YL, Jia R, et al · · 2017 · cited 45× · PMID 28159938 · DOI 10.18632/oncotarget.14942 -
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.
Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, et al · · 2021 · cited 31× · PMID 33546207 · DOI 10.3390/jcm10040566 -
Insights into CSF-1/CSF-1R signaling: the role of macrophage in radiotherapy.
Shang Q, Zhang P, Lei X, Du L, et al · · 2025 · cited 19× · PMID 40007537 · DOI 10.3389/fimmu.2025.1530890 -
Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).
Megdanova-Chipeva VG, Lamarca A, Backen A, McNamara MG, et al · · 2020 · cited 19× · PMID 32708210 · DOI 10.3390/cancers12071988 -
Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.
Crabtree JS. · · 2017 · cited 9× · PMID 29255447 · DOI 10.3389/fendo.2017.00341 -
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
Dasari A, Hamilton EP, Falchook GS, Wang JS, et al · · 2023 · cited 8× · PMID 37074571 · DOI 10.1007/s10637-023-01359-2
Verify or expand the search:
- PubMed search for NCT02267967
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neuroendocrine Tumors
Currently open trials in the same condition.
- NCT07404176 — Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocr · Phase 2 · recruiting
- NCT07314164 — Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment · recruiting
- NCT07272512 — Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms · Phase 4 · recruiting
- NCT06735560 — Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN · NA · recruiting
- NCT06889493 — SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Dif · Phase 1 · recruiting
Other Hutchison Medipharma Limited trials
Trials by the same sponsor.
- NCT05509699 — Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer · Phase 2 · completed
- NCT05318820 — A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manuf · EARLY_PHASE1 · completed
- NCT05277454 — Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT · Phase 1 · unknown
- NCT05015608 — Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification · Phase 3 · active not recruiting
- NCT05029635 — Phase III Study on HMPL-523 for Treatment of ITP · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02267967 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hutchison Medipharma Limited
- Last refreshed: 13 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02267967.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing